Skip to main content

Table 1 Demographics, baseline clinical data, and baseline CT scores in total cohort

From: Impact of baseline clinical and radiological features on outcome of chronic rhinosinusitis in granulomatosis with polyangiitis

  Total, No baseline osteitis, Baseline osteitis,
  n = 116 n = 63 n = 53
Demographic data
Women; n (%) 53 (46) 32 (51) 21 (40)
Limited GPA, as defined in WGET research group; n (%) 52 (45) 26 (41) 26 (49)
Mean age at diagnosis in years (SD) 45 (19) 45 (20) 46 (19)
Median time in years between symptom onset and diagnosis (range) 0.5 (0.0–10.0) 0.5 (0.0–9.3) 0.5 (0.0–10.0)
  Missing = 1 Missing = 1 Missing = 0
Median time in years from diagnosis to first CT (range) 0.3 (−3.9–24.6) 0.0 (−3.9–18.5) 0.8 (−1.3–24.6)
Ever smokers; fraction (%) 48/94 (51) 26/51 (51) 22/43 (51)
Mortality; n (%) 10 (9) 4 (6) 6 (11)
Laboratory data
ANCA positive; fraction (%) 109/110 (99) 62/63 (98) 47/47 (100)
ANCA negative; fraction (%) 1/110 (0.9) 1/63 (1.6) 0/47 (0)
Clinical data, BVAS
General; n (%) 107 (92) 56 (89) 51 (96)
Cutaneous; n (%) 26 (22) 15 (24) 11 (21)
Mucosal membranes/eyes; n (%) 33 (28) 19 (30) 14 (26)
Ear, nose, and throat; n (%) 107 (92) 59 (94) 48 (91)
Bloody nasal discharge/crusts/ulcers/granulomata; n (%) 93 (80) 50 (79) 43 (81)
Paranasal sinus involvement; n (%) 79 (68) 37 (59) 42 (79)
Subglottic stenosis; n (%) 0 (0) 0 (0) 0 (0)
Conductive hearing loss; n (%) 33 (28) 23 (37) 10 (19)
Sensorineural hearing loss; n (%) 7 (6) 7 (11) 0 (0)
Chest; n (%) 69 (59) 36 (57) 33 (62)
Cardiovascular; n (%) 1 (1) 1 (2) 0 (0)
Abdominal; n (%) 6 (5) 4 (6) 2 (4)
Renal; n (%) 62 (53) 34 (54) 28 (53)
Nervous system; n (%) 21 (18) 13 (21) 8 (15)
Surgery before baseline
Sinus surgery; n (%) 12 (10) 1 (2) 11 (21)
CT scores
Median GOSS (range) 0 (0–38) 0 (0–0) 4 (1–38)
Sinonasal destructions; n (%) 29 (25) 5 (8) 24 (45)
Median LM-score (range) 3 (0–22) 2 (0–13) 6 (0–22)
LM-score >0; n (%) 95 (82) 44 (70) 51 (96)
  1. Missing data on ANCA and smoking
  2. Abbreviations:GPA granulomatosis with polyangiitis, WGET Wegener’s Granulomatosis Etanercept Trial, ANCA anti-neutrophil cytoplasmic antibodies, BVAS Birmingham Vasculitis Activity Score, version 3, GOSS Global Osteitis Scoring Scale, LM-score Lund-Mackay score